Overview

Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the effect of intranasal lidocaine on pain score in pediatric patients with migraine. Patients with significant pain after oral analgesics and plan for intravenous (IV) abortive therapy will be asked to participate. Half of patients will be given intranasal lidocaine and the other half will be given placebo. Pain scores and associated migraine symptoms (i.e. nausea, vomiting, photophobia, phonophobia, avoidance of activities, and aura) will be monitored and compared between the groups.
Phase:
Phase 3
Details
Lead Sponsor:
New York City Health and Hospitals Corporation
Treatments:
Lidocaine
Pharmaceutical Solutions